Key statistics
As of last trade Supernus Pharmaceuticals Inc (0LB2:LSE) traded at 50.75, -11.90% below its 52-week high of 57.60, set on Oct 30, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | -- |
|---|---|
| High | 50.75 |
| Low | 50.75 |
| Bid | -- |
| Offer | -- |
| Previous close | 50.75 |
| Average volume | 33.29 |
|---|---|
| Shares outstanding | 57.34m |
| Free float | 54.89m |
| P/E (TTM) | -- |
| Market cap | 2.86bn USD |
| EPS (TTM) | -0.3408 USD |
Data delayed at least 20 minutes, as of Feb 12 2026 16:40 GMT.
More ▼
- Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026
- Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference
- Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference
- Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London
- Supernus Announces Third Quarter 2025 Financial Results
- Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
- Supernus Pharmaceuticals to Participate in September Investor Conferences
- Supernus Announces Second Quarter 2025 Financial Results
- Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
- Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
More ▼
